Table 3.
Population pharmacokinetic parameter estimates for the typical individual after administration of cladribine as; an infusion, orally or subcutaneously. The relative standards errors are given in parentheses. The estimates of intersubject variability are given as coefficients of variation (%).
| Parameter | Population average | Interindividual variability | ||
| Estimate | (RSE%)1 | Estimate % | (RSE%) | |
| Clearance (L/h) | 39.3 | (4.9) | 54 | (17) |
| V1 (L) | 71.7 | (13) | 34 | (62) |
| Q2 (L/h) | 51.1 | (6.8) | 61 | (17) |
| V2 (L) | 475 | (1.8) | 70 | (31) |
| Q3 (L/h) | 105 | (21) | 61 | (17) |
| V3 (L) | 73.6 | (13) | 61 | (17) |
| Oral Ka (h-1) | 1.31 | (14) | 75 | (50) |
| Oral F | 0.353 | (7.9) | 4.1 | (63) |
| Subcutaneous Ka (h-1) | 2.48 | (9,6) | N.E. | |
| Parameter | Infusion (RSE %) | Oral (RSE %) | Subcutaneous (RSE %) | IIV3 (RSE %) |
| Residual error2 | ||||
| Proportional | 0.191 (8.2) | 0.232(9.8) | 0.162 (8.8) | 24 (28) |
1 Rellative standard error. given as %.
2 Residual error presented as population average of estimate and relative standard error in parentheses.
3 Interindividual variability in residual variability expressed as coefficient of variation
Abbreviations: CL, clearance from central compartment; V1, V2 and V3, central and peripheral volumes of distribution, Q2 and Q3, intercompartmental clearances; Ka, absorption rate constant (hour-1); F, bioavailability of drug; N.E., not estimated